Cargando…
Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival
BACKGROUND: Immunomodulatory drugs (IMiDs), such as lenalidomide, are therapeutically active compounds that bind and modulate the E3 ubiquitin ligase substrate recruiter cereblon, thereby affect steady-state levels of cereblon and cereblon binding partners, such as ikaros and aiolos, and induce many...
Autores principales: | Xu, Qinqin, Hou, Yue-xian, Langlais, Paul, Erickson, Patrick, Zhu, James, Shi, Chang-Xin, Luo, Moulun, Zhu, Yuanxiao, Xu, Ye, Mandarino, Lawrence J., Stewart, Keith, Chang, Xiu-bao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855823/ https://www.ncbi.nlm.nih.gov/pubmed/27142104 http://dx.doi.org/10.1186/s12885-016-2331-0 |
Ejemplares similares
-
Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma
por: Chang, Xiubao, et al.
Publicado: (2017) -
Reproducibility of an HPLC-ESI-MS/MS Method for the Measurement of Stable-Isotope Enrichment of in Vivo-Labeled Muscle ATP Synthase Beta Subunit
por: Everman, Sarah, et al.
Publicado: (2011) -
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019) -
Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
por: Costacurta, Matteo, et al.
Publicado: (2021) -
Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
por: Butrym, Aleksandra, et al.
Publicado: (2017)